Why Is Azitra Inc Stock (AZTR) Up Today?

Azitra Inc AZTR +28.82% ▲ stock rocketed higher on Friday after the clinical-stage biopharmaceutical company revealed details of a private placement. This private placement includes $10.5 million in initial funding from a preferred stock sale. There is also an additional $20.9 million on the table from the potential cash exercise of warrants included with these shares, bringing the total value of the private placement to approximately $31.4 million.

Claim 70% Off TipRanks Premium

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions

• Stay ahead of the market with the latest news and analysis and maximize your portfolio’s potential

The private placement includes 10,470 shares of Series A convertible non-redeemable preferred stock, Series B warrants to purchase up to 85,101,201 shares of AZTR, and Series C warrants to purchase up to 85,101,201 shares of AZTR. Each Series A convertible non-redeemable preferred share is sold alongside a Series B Warrant to purchase 8,129 shares of common stock and a Series C Warrant to purchase 8,129 shares of common stock.

The prices of these stocks and warrants were also revealed by Azitra Inc. Each share is being sold for $1,000. The warrants have exercise prices of $0.123 per share. The company will use net proceeds from this private placement for research and development, general corporate expenses, and working capital needs.

Azitra Inc Stock Soars Today

Azitra Inc stock was up 87.22% on Friday, following a 28.82% rally yesterday. The shares have fallen 33.3% year-to-date and 91.99% over the past 12 months.

With today’s news came heavy trading of AZTR stock, as more than 166 million shares changed hands, compared to a three-month average daily trading volume of about 170,000 shares.

Is Azitra Inc Stock a Buy, Sell, or Hold?

Turning to Wall Street, the analysts’ consensus rating for Azitra Inc is Moderate Buy, based on a single Buy rating over the past three months. Maxim Group analyst Jason McCarthy offers the sole coverage of AZTR stock, with a Buy rating and $1 price target, representing a potential 467.86% upside for the shares.

Disclaimer & DisclosureReport an Issue